Metanova Starts Nanobody Validation With Yalotein as NOVA Expands Beyond Small Molecules
The Bittensor SN68 project is moving nanobody submissions toward wet-lab testing as NOVA expands its drug-discovery pipeline beyond small molecules.
The Bittensor SN68 project is moving nanobody submissions toward wet-lab testing as NOVA expands its drug-discovery pipeline beyond small molecules.
While Isomorphic Labs, GSK, and Anthropic poured billions into closed AI drug discovery platforms, Metanova (SN68) spent H1 2026 screening 11 million molecules in the open, tightening its incentives, and cutting synthesis time from months to days.
Metanova partners with ONEPOT.AI to accelerate drug discovery on Bittensor, enabling SN68-generated compounds to move from AI screening to robotic synthesis in days.